INTELLIA THERAPEUTICS, INC. (NTLA) Free cash flow 2016–2025
INTELLIA THERAPEUTICS, INC. (NTLA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$395.9MFY2025 · since FY2016: $29.9M → -$395.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$395.9M | -11.6% |
| FY2024 | -$354.7M | +13.1% |
| FY2023 | -$408.1M | -17.7% |
| FY2022 | -$346.8M | -45.9% |
| FY2021 | -$237.8M | -344.5% |
| FY2020 | -$53.5M | +51.4% |
| FY2019 | -$110.0M | -62.7% |
| FY2018 | -$67.6M | +10.3% |
| FY2017 | -$75.4M | -351.7% |
| FY2016 | $29.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More NTLA financial trends
NTLA RevenueNTLA Net incomeNTLA Net marginNTLA Gross profitNTLA Gross marginNTLA Operating incomeNTLA Operating marginNTLA Operating cash flowNTLA Capital expendituresNTLA Return on equityNTLA Stock buybacksNTLA Dividends paidNTLA Total assetsNTLA Total liabilitiesNTLA Shareholders’ equityNTLA overview →